Search
Returning search results with filters:
Remove filter for
Category: Biologic or vaccine
Remove filter for
Issue: New safety information
Remove filter for
Type: Health professional risk communication
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 9 of 9 items.
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
AlertHealth professional risk communication | 2022-10-26
ZOLGENSMA (onasemnogene abeparvovec) and Fatal Cases of Acute Liver Failure
AlertHealth professional risk communication | 2022-09-12
IMVAMUNE Vaccine: Updated Storage Conditions and Shelf Life
AlertHealth professional risk communication | 2022-07-29
COMIRNATY (COVID-19 Vaccine, mRNA, also referred to as Pfizer-BioNTech COVID-19 Vaccine): New Formulation/Presentation for Use in Individuals 12 Years of Age and Older
AlertHealth professional risk communication | 2022-05-09
Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2 Omicron BA.2 Subvariant
AlertHealth professional risk communication | 2022-04-14
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
AlertHealth professional risk communication | 2022-01-07
COMIRNATY (COVID-19 Vaccine, mRNA, also referred to as Pfizer-BioNTech COVID-19 Vaccine): New Formulation for Use in Children Aged 5 Years to Less Than 12 Years
AlertHealth professional risk communication | 2021-11-19
Importation of COVID-19 Vaccine Moderna with up to 15 Doses per Vial and English-only Vial and Carton Labels (US-Labelled Supply)
AlertHealth professional risk communication | 2021-06-14